Role of platelet activating factor in development of thrombocytopenia and neutropenia in dogs with endotoxemia

American Journal of Veterinary Research

Volumn 60, Issue 2, 1999, Pages 216-221

  Tsuchiya, Ryo ^a   Kyotani, Kazumi ^a   Scott, Michael A ^b   Nishizono, Kazuya ^a   Ashida, Yoshinori ^a   Mochizuki, Toshihiko ^a   Kitao, Satoshi ^a   Yamada, Takatsugu ^a   Kobayashi, Kousaku ^a  

^a AZABU UNIVERSITY   (Japan)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPOLYSACCHARIDE; THROMBOCYTE ACTIVATING FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CELL COUNT; CONCENTRATION (PARAMETERS); DOG; ENDOTOXEMIA; NEUTROPENIA; NONHUMAN; PATHOGENESIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANIMALS; BLOOD COAGULATION TESTS; DOG DISEASES; DOGS; ENDOTOXEMIA; FEMALE; ISOQUINOLINES; LEUKOCYTE COUNT; LIPOPOLYSACCHARIDES; MALE; NEUTROPENIA; PILOT PROJECTS; PLATELET ACTIVATING FACTOR; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PYRIDINIUM COMPOUNDS; RADIOIMMUNOASSAY; TETRAHYDROISOQUINOLINES; THROMBOCYTOPENIA;

ANIMALIA; BACTERIA (MICROORGANISMS); CANIS FAMILIARIS; NEGIBACTERIA;

EID: 0033039953     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Hall LW. Shock. In: Phillipson AT, Hall LW, Pritchard WR. eds. Scientific foundation of medicine. London: Heineman Medical Books, 1980;322-327.
2. Hardie EM. Endotoxemia. In: Greene CE, ed. Infectious diseases of the dog and cat. Philadelphia: WB Saunders Co, 1990;494-497.
3. Hinshow LB, Solomon LA, Freeny PC, et al. Endotoxin shock - hemodynamic and survival effects of methylprednisolone. Arch Surg 1967;94:61-66.
4. Bregengard C, Nordfang O, Wildgoose P, et al. The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits Blood Coagul Fibrinol 1993;4:699-706.
5. Green RA. Hemostatic disorders: coagulopathies and thrombotic disorders. In: Ettinger SJ, ed. Textbook of veterinary internal medicine. 3rd ed. Philadelphia: WB Saunders Co, 1989;2246-2264.
6. Hardie EM, Rawlings CA, Collins LG. Canine Escherichia coli peritonitis: long-term survival with fluid, gentamicin sulfate, and flunixin meglumine treatment. J Am Anim Hosp Assoc 1985;21: 691-699.
7. Jain NC. Essentials of veterinary hematology. Philadelphia: Lea & Febiger, 1993;97-100.
8. Ledingham IM, Routh GS. The pathophysiology of shock. Br J Hosp Med 1979;21:472-476.
9. Chang S, Voekel NF. The role of platelet-activating factor in endotoxic shock and lung injury. In: Handley DA, Saunders RN, Houlihan WJ, et al, eds. Platelet-activating factor in endotoxin and immune diseases. New York: Marcel Dekker Inc, 1990;629-654.
10. Vercellotti GM, Yin KS, Nelson RD, et al. Platelet-activating factor primes neutrophil responses to agonists: role in promoting neutrophil-mediated endothelial damage Blood 1988;71:1100-1107.
11. Wrad PA, Till GO, Kunkel B, et al. Evidence for role of hydroxyl radical in complement and neutrophil-dependent tissue injury. J Clin invest 1983;72:789-801.
12. Gutmann FD, Murthy VS, Wojciechowski MT, et al. Transient pulmonary platelet sequestration during endotoxemia in dogs. Circ Shock 1987;21:185-195.
13. While GL, White GS, Kosanke SD, et al. Therapeutic effects of prednisolone sodium succinate vs dexamethasone in dogs subjected to E. coli septic shock. J Am Anim Hosp Assoc 1982;18:639-648.
14. Handley DA. Platelet activating factor as a mediator of endotoxin-related diseases. In: Handley DA, Saunders RN, Houlihan WJ et al, eds. Platelet-activating factor in endotoxin and immune diseases. New York: Marcel Dekker Inc. 1990;451-495.
15. Moore JN, Hardee MM, Hardee GE. Modulation of arachidonic acid metabolism in endotoxic horses: comparison of flunixin meglumine, phenylbutazone, and a selective thromboxane synthetase inhibitor. Am J Vet Res 1987;47:110-113.
16. Yamashita K, Fujinaga T, Hagio M, et al. Bioassay for interleukin-1, interleukin-6, and tumor necrosis factor-like activities in canine sera. J Vet Med Sci 1994;56:103-107.
17. Sun X, Hsueh W, Torre-Amione G. Effects of in vivo priming on endotoxin-induced hypotension and tissue injury: the role of PAF and tumor necrosis factor. Am J Pathol 1990;136:949-956.
18. Sun X, Wei H. Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor. J Clin Invest 1988;81:1328-1331.
19. Chang S, Fedderson CO, Henson PM, et al. Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest 1987,79:1498-1509.
20. Doebber TW, Wu MS, Robbins JC, et al. Platelet activating factor (PAF) involvement in endotoxin-induced hypotention in rats. Studies with PAF-receptor antagonist kadsulenon. Biochem Biophys Res Comm 1985;127:799-808.
21. Warren JS, Barton PA, Mandel DM, et al. Intrapulmonary tumor necrosis factor triggers local platelet-activating factor production in rat immune complex alveolitis. Lab Invest 1990;63:746-754.
22. McManus L, Hanahan DJ, Demopoulos CA, et al. Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine, a synthetic platelet-activating factor (PAF), in the rabbit. J Immunel 1980;124:2919-2924.
23. Feingold HM, Pivacek LE, Melaragno AJ, et al. Coagulation assays and platelet aggregation patterns in human, baboon, and canine blood. Am J Vet Res 1986;47:2197-2199.
24. Meyers KM. Pathobiology of animal platelets. Adv Vet Sci Comp Med 1985;30:131-165.
25. Janero DR, Buerghardt B, Burghaartt C. Specific binding of 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) to the intact canine platelet. Thromb Res 1988;50:789-802.
26. Tahraoui L, Floch A, Mondot S, et al. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation. Mol Pharmacol 1988;34:145-151.
27. Herman F, Mayer K, Filep JG. In vivo antiaggregatory action of platelet-activating factor in Beagle dogs: role for prostacyclin. Thromb Haemost 1991;65:296-299.
28. Shaw JO, Pinvkard RN, Ferrigni KS, et al. Activation of human neutrophils with 1-0-hexadecyl/octadecyl-2-acetyl-sn-3-phosphorylcholine (platelet activating factor). J Immunol 1981;127: 1250-1255.
29. Taketani M, Maezaki N, Imura Y, et al. Platelet activating factor (PAF) antagonists: development of a highly potent PAF antagonist, TCV-309. Adv Prostagland Thrombox Leukot Res 1990;21: 943-946.
30. Terashita Z, Imura Y, Taketani M, et al. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents J Pharmacol Exp Ther 1992;260:748-755.
31. O'Rourke ST, Folts JD, Albrecht RM. Inhibition of canine platelet aggregation by barbiturates. J Lab Clin Med 1986;108:206-212.
32. Barrangry TB. Veterinary drug therapy. Philadelphia: Lea & Febiger, 1994;188-199.
33. Swango LJ, Bankemper KW, Kong LI. Bacterial, rickettsial, protozoal and miscellaneous infections. Textbook of veterinary internal medicine. 3rd ed. Philadelphia: WB Saunders Co, 1989;265-297.
34. Brown SA. Treatment of gram-negative infections. Vet Clin North Am Small Anim Pract 1988;18:1141-1165.
35. Bessin P, Bonnet J, Apffel D, et al. Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs. Eur J Pharmacol 1983;86:403-413
36. Otsuka A, Masugi F, Ogihara T, et al. Hypotensive mechanism of acetyl glyceryl ether phosphocholine (AGEPC) in dogs. Effects on hemodynamics and humoral factors. Prostaglandins Leukot Med 1985;19:25-35.
37. Sybertz EJ, Watkins RW, Baum T, et al Cardiac, coronary and peripheral vascular effects of acetyl gliceryl ether phospholylcholine in the anathetized dog. J Prharmacol Exp Ther 1984;232: 156-162.
38. Vemulapalli S, Chiu PJS, Barnett A. Cardiovascular and renal action of platelet-activating factor in anesthetized dogs. Hypertension 1984;6:489-493.
39. Yamanaka S, Miura K, Yukimura T, et al. Putative mechanism of hypotensive action of platelet-activating factor in dogs. Circ Res 1992;70:893-901.
40. Watkins RW, Braun T, Pula K, et al. Cardiac, coronary, and peripheral vascular effects of AGEPC in the anesthetized dog. J Pharmacol Exp Ther 1985;232:156-162.
41. Jacson CV, Schumacher WA, Kunkel SL, et al. Platelel-activating-factor and the release of a platelet-delived coronary artery vasodilator substance in the canine. Circ Res 1986;58:218-229.
42. Pearson JM, Schultze AE, Jean PA, et al. Platelet participation in liver injury from gram-negative bacterial lipopolysaccharide in the rat. Shock 1995;4:178-186.
43. Weiss M, Buhl R, Mirow N, et al. Do barbiturates impair zymosan-induced granulocyte function? J Crit Care 1994;9:83-89.
44. Sostman HD, Zoghbi SS, Smith GJ, et al. Platelet kinetics and biodistribution in canine endotoxemia. Invest Radiol 1983;18:425-435.
45. 125I-labeled endotoxin to bovine, canine, and equine platelets and endotoxin-induced agglutination of canine platelets. Am J Vet Res 1982;43: 1721-1728.
46. Garner R, Chater BV, Brown DL. The role of complement in endotoxin shock and disseminated intravascular coagulation: experimental observations in the dog. Br J Haematol 1974;28:393-401.